桂林三金(002275.SZ)拟向上海三金增资7500万元 后者再向宝船生物进行增资
格隆汇 12 月 28日丨桂林三金(002275.SZ)公布,为进一步满足全资孙公司宝船生物医药科技(上海)有限公司(“宝船生物”)经营发展需要,增强生物板块研发实力,公司拟使用自有资金向全资子公司上海三金生物科技有限公司(“上海三金”)增资7500万元,用于上海三金增资全资孙公司宝船生物。此次增资完成后,上海三金注册资本由5000万元增加至1.25亿元,宝船生物注册资本由4101.0597万元增加至11,601.0597万元。
公司此次使用自用资金对全资子公司增资,全资子公司再对全资孙公司进行增资,是为了满足孙公司宝船生物的经营发展需要,有利于促进公司研发业务的顺利开展与实施,符合公司及全体股东的利益。此次增资系对公司合并报表范围内的全资子公司和全资孙公司增资,不会对公司的财务状况和经营成果造成重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.